Definium says LSD therapy DT120 eased anxiety in second late-stage trial
Definium Therapeutics said its LSD therapy DT120 helped patients with anxiety in a second late-stage trial.
Why it matters: The reported 5.1-point gap between DT120 and placebo mirrors the company's first late-stage anxiety study, so the pending regulatory filing will test whether that effect size holds up in a review.